← Leaderboards
Peter A Barry
University Of California Davis
$19,847,796
Attributed
$30,300,753
Total exposure
35
Grants
20
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.3M · FY2005–20$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
Funding mix
By agency
NIH$37,664,381 · 37
By mechanism
R01$22,721,790 · 8
P01$9,806,625 · 3
P51$2,240,967 · 19
R21$1,572,708 · 4
R56$1,173,791 · 2
R03$148,500 · 1
Top collaborators
- Mark R Walter11 shared
- Ellen Elizabeth Sparger10 shared
- Don J Diamond9 shared
- Barbara L Shacklett5 shared
- Dennis J Hartigan-O'Connor3 shared
- Stephen Charles Noctor3 shared
- Sallie R. Permar3 shared
- Alice F Tarantal3 shared
Most similar at University Of California Davis
Same institution · by research overlap
- Nicholas W Lerche$24,728,788
- Marta L Marthas$7,401,608
Others in their field
Top investigators on “Cytomegalovirus”
- Constance Ann Benson · University Of California, San Diego$154,530,762
- Curtis L Meinert · Johns Hopkins University$72,267,482
- Louis J. Picker · Oregon Health And Science University$67,787,971
- Robert Turner Schooley · University Of Colorado Denver$42,307,156
- Dan H. Barouch · Fred Hutchinson Cancer Center$34,316,808
- Jay A Nelson · Oregon Health & Science University$28,085,685
Research focus
CytomegalovirusMacaca MulattaInfectionVaccinesImmuneViralVirusImmune ResponseImmunizationCytomegalovirus VaccinesImmunityNatural HistoryAntigensPreventBaseVaccinationVariantCongenital InfectionClinical TrialsNonhuman PrimateAttenuatedPrimatesCytomegalovirus InfectionsSite
Grant awards (90)
Immunologic and virologic determinants of congenital Cytomegalovirus transmission and disease in rhesus monkeys$188,956
P01 · FY2020 · AI
Immunologic and virologic determinants of congenital Cytomegalovirus transmission and disease in rhesus monkeys$12,517
P01 · FY2020 · AI
Immunologic and virologic determinants of congenital Cytomegalovirus transmission and disease in rhesus monkeys$2,863,852
P01 · FY2019 · AI
Role of reservoir composition and T cell immunity in HIV rebound kinetics$1,398,678
P01 · FY2019 · AI
Role of reservoir composition and T cell immunity in HIV rebound kinetics$1,415,389
P01 · FY2018 · AI
CMV-vectored Vaccine Approaches to Induce Protective Antibodies to HIV-1 Env$186,899
R21 · FY2018 · AI · contact PI
Role of reservoir composition and T cell immunity in HIV rebound kinetics$1,484,236
P01 · FY2017 · AI
Prevention of Primary HCMV Infection by Vaccinating against HCMV-Encoded IL-10$656,439
R01 · FY2017 · AI · contact PI
CMV-vectored Vaccine Approaches to Induce Protective Antibodies to HIV-1 Env$232,677
R21 · FY2017 · AI · contact PI
Leveraging Established Fetal Primate Models to Expedite ZIKV Investigations$220,020
R21 · FY2017 · OD
Leveraging Established Fetal Primate Models to Expedite ZIKV Investigations$100,356
R21 · FY2017 · OD
HCMV Vaccine produced from BAC-MVA that Blocks Epithelial and Fibroblast Entry$724,200
R01 · FY2016 · AI
Prevention of Primary HCMV Infection by Vaccinating against HCMV-Encoded IL-10$680,407
R01 · FY2016 · AI · contact PI
Vaccine-mediated Targeting of Viral IL10 to Control HCMV Shedding and Reinfection$636,633
R01 · FY2016 · AI · contact PI
Leveraging Established Fetal Primate Models to Expedite ZIKV Investigations$193,000
R21 · FY2016 · OD
Impact of chronic viral infections and altered microbiota on HIV vaccine efficacy$773,051
R56 · FY2015 · AI
HCMV Vaccine produced from BAC-MVA that Blocks Epithelial and Fibroblast Entry$737,660
R01 · FY2015 · AI
Prevention of Primary HCMV Infection by Vaccinating against HCMV-Encoded IL-10$735,112
R01 · FY2015 · AI · contact PI
Vaccine-mediated Targeting of Viral IL10 to Control HCMV Shedding and Reinfection$632,681
R01 · FY2015 · AI · contact PI
In Vivo Characterization of the Pathogenesis of Modified RhCMV Vectors (Pathogene$562,631
P01 · FY2015 · AI · contact PI
Attenuated RhCMV Delta 10 SIV Oral Vaccine Vectors Encoding TLR5 Ligand Sequences$548,792
R01 · FY2015 · DE
Prevention of Primary HCMV Infection by Vaccinating against HCMV-Encoded IL-10$753,403
R01 · FY2014 · AI · contact PI
HCMV Vaccine produced from BAC-MVA that Blocks Epithelial and Fibroblast Entry$750,339
R01 · FY2014 · AI
Attenuated RhCMV Delta 10 SIV Oral Vaccine Vectors Encoding TLR5 Ligand Sequences$645,317
R01 · FY2014 · DE
Vaccine-mediated Targeting of Viral IL10 to Control HCMV Shedding and Reinfection$629,713
R01 · FY2014 · AI · contact PI
In Vivo Characterization of the Pathogenesis of Modified RhCMV Vectors (Pathogene$598,885
P01 · FY2014 · AI · contact PI
Evaluation of Protective CMV Vaccines in Rhesus Macaques$565,290
R01 · FY2014 · AI · contact PI
HCMV Vaccine produced from BAC-MVA that Blocks Epithelial and Fibroblast Entry$614,609
R01 · FY2013 · AI
Attenuated RhCMV Delta 10 SIV Oral Vaccine Vectors Encoding TLR5 Ligand Sequences$613,281
R01 · FY2013 · DE
Vaccine-mediated Targeting of Viral IL10 to Control HCMV Shedding and Reinfection$583,894
R01 · FY2013 · AI · contact PI
Evaluation of Protective CMV Vaccines in Rhesus Macaques$528,777
R01 · FY2013 · AI · contact PI
In Vivo Characterization of the Pathogenesis of Modified RhCMV Vectors (Pathogene$451,260
P01 · FY2013 · AI · contact PI
Prevention of Primary HCMV Infection by Vaccinating against HCMV-Encoded IL-10$284,333
R01 · FY2013 · AI · contact PI
Evolution and Emergence of Simian Retroviruses in South Asia$674,995
R01 · FY2012 · AI
Vaccine-mediated Targeting of Viral IL10 to Control HCMV Shedding and Reinfection$624,587
R01 · FY2012 · AI · contact PI
Attenuated RhCMV Delta 10 SIV Oral Vaccine Vectors Encoding TLR5 Ligand Sequences$616,708
R01 · FY2012 · DE
Evaluation of Protective CMV Vaccines in Rhesus Macaques$504,976
R01 · FY2012 · AI · contact PI
In Vivo Characterization of the Pathogenesis of Modified RhCMV Vectors (Pathogene$444,156
P01 · FY2012 · AI · contact PI
Prevention of Primary HCMV Infection by Vaccinating Against HCMV-Encoded IL-10$400,740
R56 · FY2012 · AI · contact PI
Evolution and Emergence of Simian Retroviruses in South Asia$687,944
R01 · FY2011 · AI
Attenuated RhCMV Delta 10 SIV Oral Vaccine Vectors Encoding TLR5 Ligand Sequences$623,184
R01 · FY2011 · DE
Evaluation of Protective CMV Vaccines in Rhesus Macaques$615,364
R01 · FY2011 · AI · contact PI
In Vivo Characterization of the Pathogenesis of Modified RhCMV Vectors (Pathogene$386,065
P01 · FY2011 · AI · contact PI
EVALUATION OF PROTECTIVE CMV VACCINES IN RHESUS MACAQUES$191,444
P51 · FY2011 · RR · contact PI
Development and Immunogenicity of Attenuated RhCMVdelta10 Vaccine Vectors$189,857
R21 · FY2011 · AI
A NON-HUMAN PRIMATE MODEL FOR CYTOMEGALOVIRUS VACCINES$143,611
P51 · FY2011 · RR · contact PI
CONGENITAL TRANSMISSION OF RHESUS CMV IN RHESUS MACAQUES$143,611
P51 · FY2011 · RR · contact PI
Evaluation of Protective CMV Vaccines in Rhesus Macaques$585,050
R01 · FY2010 · AI · contact PI
A Non-Human Primate Model for Cytomegalovirus Vaccines$400,912
R01 · FY2010 · AI · contact PI
Development and Immunogenicity of Attenuated RhCMVdelta10 Vaccine Vectors$229,586
R21 · FY2010 · AI
EVALUATION OF PROTECTIVE CMV VACCINES IN RHESUS MACAQUES$152,094
P51 · FY2010 · RR · contact PI
A NON-HUMAN PRIMATE MODEL FOR CYTOMEGALOVIRUS VACCINES$114,105
P51 · FY2010 · RR · contact PI
A Non-Human Primate Model for Cytomegalovirus Vaccines$502,285
R01 · FY2009 · AI · contact PI
Evaluation of Protective CMV Vaccines in Rhesus Macaques$353,462
R01 · FY2009 · AI · contact PI
EVALUATION OF PROTECTIVE CMV VACCINES IN RHESUS MACAQUES$146,580
P51 · FY2009 · RR · contact PI
A NON-HUMAN PRIMATE MODEL FOR CYTOMEGALOVIRUS VACCINES$109,904
P51 · FY2009 · RR · contact PI
A Non-Human Primate Model for Cytomegalovirus Vaccines$405,662
R01 · FY2008 · AI · contact PI
Evaluation of Protective CMV Vaccines in Rhesus Macaques$353,462
R01 · FY2008 · AI · contact PI
EVALUATION OF PROTECTIVE CMV VACCINES IN RHESUS MACAQUES$168,995
P51 · FY2008 · RR · contact PI
A NON-HUMAN PRIMATE MODEL FOR CYTOMEGALOVIRUS VACCINES$126,722
P51 · FY2008 · RR · contact PI
A Non-Human Primate Model for Cytomegalovirus Vaccines$411,232
R01 · FY2007 · AI · contact PI
Evaluation of Protective CMV Vaccines in Rhesus Macaques$359,716
R01 · FY2007 · AI · contact PI
EVALUATION OF PROTECTIVE CMV VACCINES IN RHESUS MACAQUES$82,029
P51 · FY2007 · RR · contact PI
A NON-HUMAN PRIMATE MODEL FOR CYTOMEGALOVIRUS VACCINES$82,027
P51 · FY2007 · RR · contact PI
Evaluation of Protective CMV Vaccines in Rhesus Macaques$369,849
R01 · FY2006 · AI · contact PI
A Non-Human Primate Model for Cytomegalovirus Vaccines$348,154
R01 · FY2006 · AI · contact PI
A NON-HUMAN PRIMATE MODEL FOR CYTOMEGALOVIRUS VACCINES$99,319
P51 · FY2006 · RR · contact PI
POST-EXPOSURE VACCINATION FOR HCMV INFECTION$99,319
P51 · FY2006 · RR · contact PI
COMPARATIVE IMMUNIZATION FOR SIMIAN HERPESVIRUSES$99,319
P51 · FY2006 · RR · contact PI
A Non-Human Primate Model for Cytomegalovirus Vaccines$405,437
R01 · FY2005 · AI
Evaluation of Protective CMV Vaccines in Rhesus Macaques$375,000
R01 · FY2005 · AI
COMPARATIVE IMMUNIZATION FOR SIMIAN HERPESVIRUSES$110,902
P51 · FY2005 · RR
POST-EXPOSURE VACCINATION FOR HCMV INFECTION$110,902
P51 · FY2005 · RR
A NON-HUMAN PRIMATE MODEL FOR CYTOMEGALOVIRUS VACCINES$110,902
P51 · FY2005 · RR
A Non-Human Primate Model for Cytomegalovirus Vaccines$454,338
R01 · FY2004 · AI
A NON-HUMAN PRIMATE MODEL FOR CYTOMEGALOVIRUS VACCINES$115,658
P51 · FY2004 · RR
POST-EXPOSURE VACCINATION FOR HCMV INFECTION$18,948
P51 · FY2004 · RR
A Non-Human Primate Model for Cytomegalovirus Vaccines$484,010
R01 · FY2003 · AI
Post-Exposure Vaccination for HCMV Infection$74,250
R03 · FY2003 · AI
A NON-HUMAN PRIMATE MODEL FOR CYTOMEGALOVIRUS VACCINES$14,576
P51 · FY2003 · RR
A Non-Human Primate Model for Cytomegalovirus Vaccines$405,933
R01 · FY2002 · AI
Post-Exposure Vaccination for HCMV Infection$74,250
R03 · FY2002 · AI
DEVELOPMENTAL SUSCEPTIBILITY OF FETAL BRAIN TO CMV$7,419
R01 · FY2002 · NS
DEVELOPMENTAL SUSCEPTIBILITY OF FETAL BRAIN TO CYTOMEGALOVIRUS$0
P51 · FY2002 · RR
DEVELOPMENTAL SUSCEPTIBILITY OF FETAL BRAIN TO CMV$249,985
R01 · FY2001 · NS
DEVELOPMENTAL SUSCEPTIBILITY OF FETAL BRAIN TO CYTOMEGALOVIRUS$0
P51 · FY2001 · RR
DEVELOPMENTAL SUSCEPTIBILITY OF FETAL BRAIN TO CMV$293,446
R01 · FY2000 · NS
CYTOMEGALOVIRUS &CYTOKINES--COFACTORS IN HIV ACTIVATION$237,800
R01 · FY2000 · HL
AUGMENTATION OF ANTI-SIV IMMUNITY BY A BYSTANDER EFFECT$220,313
R21 · FY2000 · AI
DEVELOPMENTAL SUSCEPTIBILITY OF FETAL BRAIN TO CMV$50,000
R01 · FY2000 · NS